Duchenne muscular dystrophy gene carrier
Not recruitingStudy to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment
Study to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment
- Disease:Duchenne muscular dystrophy gene carrier
- Substances:Vesleteplirsen
Italy- Participants:0–17 years · 18–64 years
- Substances:Vesleteplirsen
- Sponsor:Sarepta Therapeutics Inc.













